Sign In
Buy MRSN
$29.08
+0 (+0%)
At Close: Apr 02, 2026
Xconomy: ADC’s $233M IPO Brings It to NYSE With Cancer Drug Launch on Horizon
06:22pm, Friday, 15'th May 2020
ADC Therapeutics is making its public markets debut, raising about $233 million six months after the cancer drug developer withdrew its initial IPO plans.
Mersana Therapeutics to Present Two Posters at the American Association for Cancer Research 2020 Virtual Annual Meeting
12:00pm, Friday, 15'th May 2020
CAMBRIDGE, Mass., May 15, 2020 -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of.
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
11:00am, Friday, 15'th May 2020
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today reported fin
Mersana Therapeutics Announces Initiation of XMT-1592 Phase 1 Dose Escalation Study
08:05pm, Thursday, 14'th May 2020
Mersana Therapeutics, Inc. (MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unm
Takeda to Present Data at Upcoming Virtual Scientific Congresses, Underscoring Breadth of Oncology Portfolio and Emerging Pipeline
05:00pm, Thursday, 14'th May 2020
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”) today announced that the company will present data from its expanding oncology pipeline...
ADC Therapeutics sets IPO terms, to be valued at up to $1 billion
10:56am, Thursday, 14'th May 2020
ADC Therapeutics S.A. undefined set terms of its initial public offering, as the Switzerland-based biotechnology company focused on cancer treatments looks...
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Commission (EC) extended the current conditiona
Mersana Therapeutics, Inc. (MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unm
8 Overlooked REITs Beating The Crisis
11:45am, Wednesday, 13'th May 2020
We search for REITs with dislocations between price and fundamentals. These particular REITs are resilient through this environment making the cheap prices oppo
Daiichi Sankyo to Present New Research Data Across DXd ADC Portfolio at 2020 ASCO Annual Meeting
12:00am, Wednesday, 13'th May 2020
Daiichi Sankyo to present new research data across DXd ADC portfolio at 2020 ASCO Annual Meeting.
